
AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland

